Back grey_arrow_rt.gif
 
 
New Low Dose Interferon Drug for HBV Enters Study
 
 
  Amarillo Biosciences Enters Into License and Supply Agreement With CytoPharm for Low Dose Oral Interferon Use in Influenza and Hepatitis B in China and Taiwan
 
CytoPharm to Conduct Clinical Trials and Seek Regulatory Approval for Amarillo Biosciences' Low Dose Oral Interferon

 
AMARILLO, TX and TAIPEI, TAIWAN -- (MARKET WIRE) -- November 27, 2006 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has entered into a License and Supply Agreement with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization.
 
Under the terms of the Agreement, CytoPharm and its subsidiary will conduct all clinical trials, and seek to obtain regulatory approvals in both China and Taiwan (the Territory) to launch ABI's low dose oral interferon in the Territory for influenza and hepatitis B (HBV) indications. CytoPharm has entered into discussions with regulatory agencies in the Territory to conduct clinical trials, which are expected to commence in 2007.
 
"With the fast growing economies and vastly improving health care systems in both China and Taiwan, patients' demands for newer and better drugs have become much stronger," said Dr. Ellson Chen, Chairman of CytoPharm, and founder of Vita Genomics. "HBV, known as the curse of Chinese people, is a major disease in the region, and governments spend billions of dollars and commit economic resources to deal with this deadly disease. This Agreement is the first example that CytoPharm is determined to work to improve the health and well-being in China and Taiwan."
 
Dr. Joseph M. Cummins, President and CEO of ABI, said, "This agreement is of major significance to ABI because our low dose oral interferon will be tested in patients with hepatitis B and influenza, two major diseases which impact millions of people worldwide annually. We are especially pleased by the professionalism and diligence which CytoPharm has demonstrated in our dealings to date, and are also pleased that they share our vision in the promise that our low dose oral interferon can be a therapeutic agent against a wide array of medical conditions."
 
Dr. Stephen T. Chen, President of STC International and an ABI Board member living in Taiwan, made the introduction of ABI to CytoPharm and was instrumental in negotiations of the License and Supply Agreement. "I am very pleased to see these two fine companies reach the Agreement to collaborate on the development of low dose interferon alpha. In my estimation, this product will be a huge success in the Asian marketplace," said Dr. Chen.
 
In addition, Dr. Z. John Gu, CEO of CytoPharm, commented, "The Agreement enables CytoPharm to continue its work on cytokine therapeutic uses, particularly in the areas of hepatitis, and other viral infections. This collaboration provides mutual benefits during commercializing low dose oral IFN. It also demonstrates CytoPharm's vision in working on biopharmaceuticals for pursuing better health in the regions."
 
"CytoPharm will conduct important clinical studies to demonstrate the efficacy of low dose oral interferon against influenza and hepatitis B," said Dr. Claus Martin, Special Consultant to ABI. "The clinical data generated will provide invaluable assistance in our efforts to bring low dose oral interferon into a number of countries with whom we have been holding discussions, including Thailand, Brunei, Myanmar, the Philippines, Malaysia, Singapore and Indonesia."
 
Financial arrangements have not been disclosed, but according to the Agreement, CytoPharm will make payments to ABI upon reaching certain milestones and will also pay royalties on low dose oral interferon sales in the Territory.
 
About CytoPharm
 
CytoPharm is a closely held company focusing on the development of biopharmaceuticals for virus-infected diseases and cancers. It was founded in 2002 by Ho Tung Chemical, Vita Genomics, and banks and venture capital firms. It acquired core technologies from GeneTrol Therapeutics, Inc., a California-based company through M&A. Its product pipelines contain a series of cytokines induced by its proprietary technologies, used for hepatitis, and cancers. Currently, its product is under clinical trials in China. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Inc., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2005 revenues exceeded NTD 35 billion.
 
About Amarillo Biosciences, Inc.
 
Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.
 
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.
 
Media Contacts:
Z. John Gu, PhD
CytoPharm, Inc.
Tel: (858) 342-1641
Fax: (858) 755-1128
Email: Email Contact
 
Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: (806) 376-1741
Fax: (806) 376-9301
Email: Email Contact
 
Investor Relations:
David Mu
CytoPharm, Inc.
Tel: (886) 2 8976-9628
Fax: (886) 2 8976-9629
Email: Email Contact
 
Philippe Niemetz
PAN Consultants, Ltd.
Tel: (800) 477-7570
(212) 344-6464
Fax: (212) 618-1276
Email: Email Contact
 
SOURCE: Amarillo Biosciences, Inc.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org